Syros Pharmaceuticals, Inc. (SYRS) Q2 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Cirrus Pharmaceuticals' second quarter 2023 financial results conference call. At this time, all participants are in listen-only mode. This call is being webcast live on the Investors and Media section of Cirrus' website at www.cirrus.com. Please be advised that today's call is being recorded. At this time, I would like to turn the call over to Karen Hanady, Director of Investor Relations and Corporate Communications at Cirrus. Please go ahead. Thank you. This morning, we issued a press release announcing our second quarter 2023 financial results. The full release is available on the Investors and Media section of Cirrus' website at www.cirrus.com. We will begin the call with prepared remarks by Dr. Nancy Simonian, our Chief Executive Officer, Dr. David Roth, our Chief Medical Officer, and Jason Haas, our Chief Financial Officer. We will then open the call for questions. Kristen Stevens, our Chief Development Officer, Dr. Eric Olson, our Chief Scientific Officer, and Conley Chee, our Chief Commercial Officer, are also on the call and will be available for Q&A. Before we begin, I would like to remind everyone that the statements we make on this conference call will include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those set forth in the risk factors section of our quarterly report on Form 10-Q that we filed this morning, our annual report on Form 10-K that we filed earlier in the year, and any other filings that we may make with the SEC in the future. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our v...